Total Payments
$554,495
2024 Payments
$58,118
Companies
44
Transactions
2,326
Medicare Patients
3,434
Medicare Billing
$2.0M
Payment Breakdown by Category
Other$430,907 (77.7%)
Travel$56,753 (10.2%)
Food & Beverage$44,634 (8.0%)
Consulting$21,930 (4.0%)
Education$271.27 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $355,529 | 193 | 64.1% |
| Honoraria | $75,378 | 53 | 13.6% |
| Travel and Lodging | $56,753 | 132 | 10.2% |
| Food and Beverage | $44,634 | 1,923 | 8.0% |
| Consulting Fee | $21,930 | 12 | 4.0% |
| Education | $271.27 | 13 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $100,965 | 268 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $77,036 | 117 | $0 (2024) |
| PFIZER INC. | $69,538 | 246 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $62,225 | 242 | $0 (2024) |
| UCB, Inc. | $49,196 | 176 | $0 (2024) |
| Horizon Pharma plc | $45,010 | 93 | $0 (2018) |
| Horizon Therapeutics plc | $44,324 | 126 | $0 (2023) |
| GlaxoSmithKline, LLC. | $40,499 | 107 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $29,947 | 61 | $0 (2019) |
| Regeneron Healthcare Solutions, Inc. | $15,699 | 51 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $58,118 | 193 | Mallinckrodt Hospital Products Inc. ($18,367) |
| 2023 | $44,932 | 178 | Mallinckrodt Hospital Products Inc. ($20,045) |
| 2022 | $59,697 | 168 | Horizon Therapeutics plc ($16,014) |
| 2021 | $53,111 | 254 | Mallinckrodt Hospital Products Inc. ($23,584) |
| 2020 | $36,070 | 214 | Mallinckrodt Hospital Products Inc. ($8,021) |
| 2019 | $107,655 | 448 | AbbVie, Inc. ($24,163) |
| 2018 | $103,151 | 457 | Horizon Pharma plc ($31,472) |
| 2017 | $91,760 | 414 | Novartis Pharmaceuticals Corporation ($31,641) |
All Payment Transactions
2,326 individual payment records from CMS Open Payments — Page 1 of 94
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $13.29 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Travel and Lodging | Cash or cash equivalent | $34.98 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $15.17 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $13.61 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $13.22 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/09/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $8.74 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,125.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Travel and Lodging | In-kind items and services | $177.40 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $105.18 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $108.80 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $22.85 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/02/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $14.25 | General |
| Category: Inflammation | ||||||
| 11/25/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $24.97 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $105.75 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological), NUCALA | Food and Beverage | In-kind items and services | $13.61 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $10.60 | General |
| 11/20/2024 | Fresenius Kabi USA, LLC | — | Food and Beverage | In-kind items and services | $14.69 | General |
| 11/19/2024 | UCB, Inc. | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $6,440.00 | General |
| Category: Immunology | ||||||
| 11/19/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,150.00 | General |
| Category: Immunology | ||||||
| 11/19/2024 | UCB, Inc. | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $920.00 | General |
| Category: Immunology | ||||||
| 11/19/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $158.79 | General |
| Category: Immunology | ||||||
| 11/19/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $14.13 | General |
| Category: Immunology | ||||||
| 11/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $850.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/12/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $19.19 | General |
| Category: Dermatology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 732 | 22,504 | $1.2M | $389,233 |
| 2022 | 17 | 797 | 26,051 | $1.4M | $474,928 |
| 2021 | 18 | 896 | 25,695 | $1.5M | $546,613 |
| 2020 | 18 | 1,009 | 26,270 | $2.1M | $638,518 |
Total Patients
3,434
Total Services
100,520
Medicare Billing
$2.0M
Procedure Codes
71
All Medicare Procedures & Services
71 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 16 | 4,970 | $369,000 | $128,874 | 34.9% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 12 | 11,480 | $397,497 | $118,968 | 29.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 44 | 3,000 | $138,000 | $53,911 | 39.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 217 | 461 | $85,285 | $29,639 | 34.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 32 | 180 | $50,400 | $19,285 | 38.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 46 | 182 | $43,680 | $9,539 | 21.8% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 51 | 91 | $18,200 | $8,719 | 47.9% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 57 | 144 | $32,400 | $8,569 | 26.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 29 | 139 | $18,070 | $3,192 | 17.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 65 | 201 | $7,035 | $2,134 | 30.3% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 14 | 57 | $4,560 | $1,715 | 37.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $4,420 | $1,483 | 33.5% |
| 20553 | Injection of trigger points, 3 or more muscles | Office | 2023 | 18 | 31 | $7,750 | $1,244 | 16.1% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 63 | 1,376 | $13,760 | $1,146 | 8.3% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 14 | 70 | $1,400 | $383.28 | 27.4% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2023 | 17 | 19 | $665.00 | $234.65 | 35.3% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 11 | 38 | $1,112 | $156.34 | 14.1% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 13 | 52 | $2,080 | $41.13 | 2.0% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2022 | 15 | 5,220 | $415,100 | $147,474 | 35.5% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 16 | 11,912 | $411,920 | $138,931 | 33.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 62 | 6,120 | $277,440 | $103,921 | 37.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 209 | 369 | $68,265 | $24,733 | 36.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 34 | 181 | $50,680 | $20,687 | 40.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 91 | 110 | $28,600 | $8,375 | 29.3% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 60 | 136 | $31,275 | $8,339 | 26.7% |
About Dr. Edward Reardon, D.O
Dr. Edward Reardon, D.O is a Rheumatology healthcare provider based in Warwick, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2005. The National Provider Identifier (NPI) number assigned to this provider is 1760488449.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Edward Reardon, D.O has received a total of $554,495 in payments from pharmaceutical and medical device companies, with $58,118 received in 2024. These payments were reported across 2,326 transactions from 44 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($355,529).
As a Medicare-enrolled provider, Reardon has provided services to 3,434 Medicare beneficiaries, totaling 100,520 services with total Medicare billing of $2.0M. Data is available for 4 years (2020–2023), covering 71 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Warwick, RI
- Active Since 06/27/2005
- Last Updated 01/28/2013
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1760488449
Products in Payments
- ACTHAR (Biological) $106,984
- XELJANZ (Drug) $69,012
- COSENTYX (Biological) $59,873
- KRYSTEXXA (Biological) $40,687
- BENLYSTA (Biological) $40,377
- Cimzia (Drug) $36,373
- RINVOQ (Biological) $30,019
- KRYSTEXXA (Drug) $26,127
- RAYOS (Drug) $22,680
- Humira (Biological) $17,489
- KEVZARA (Biological) $9,104
- Bimzelx (Biological) $8,845
- SKYRIZI (Biological) $8,399
- KEVZARA SARILUMAB INJECTION (Biological) $7,041
- Rinvoq (Biological) $5,862
- RINVOQ (Drug) $4,292
- SIMPONI ARIA (Biological) $4,212
- KEVZARA (Drug) $3,690
- Enbrel (Biological) $1,328
- TREMFYA (Drug) $1,277
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.